Two SHP2 inhibitors are conducting clinical trials in China and the United States, Garcos Pharmaceuticals said through the Hong Kong Stock Exchange

On November 29th, information posted on the HKEx website showed that Garcos Pharmaceuticals' IPO application had been heard by HKEx.
Pharmaceuticals filed an IPO application at the end of September under Chapter 18A of the HONG Kong Stock Exchange Listing Rules, co-sponsored by Goldman Sachs and COC.
According to the post-hearing information set, the HKEx IPO, Garcos Pharmaceuticals intends to spend about 88.0% of the proceeds on the clinical development and commercialization of research products, including the variant protein tyrosine phosphatase (SHP2) inhibitors JAB-3068 and JAB-3312.
2015, the Company's Chairman and CHIEF Executive Officer is Dr. Wang Inxiang, who is focused on the independent discovery and development of the world's first innovative oncology therapy.
the company's laboratory platform has the development of protein phosphatase, KRAS and other transcription factors of the variant inhibitor technology.
, Garcos Pharmaceuticals has received investments from several biotechnology professional investment institutions, including Qiming Ventures, Lilly Asia Fund, Gao Wei Capital and Taiwan Yuyu.
two fast-moving drug development projects in the Garcos Pharmaceuticals product line -- JAB-3068 and JAB-3312.
both are variants of SHP2 inhibitors, small molecule oral anti-tumor drugs designed and developed by Garcos Pharmaceuticals with global intellectual property rights, and are currently undergoing clinical trials in China and the United States.
photo source: References in which JAB-3068 has both tumor immunity and targeted treatment mechanisms.
preclinical results show that the product alone oral administration has a very significant anti-tumor effect, can promote the function of CD8-T cells to kill tumors, can also be used in association with PD-1/PD-L1 antibodies and other drugs.
currently, Garcos Pharmaceuticals is evaluating the clinical efficacy of JAB-3068 for three types of solid tumors in Clinical Phase 2a in China.
another JAB-3312 can block kras-MAPK signaling path, but also can remove tumor immunosuppression micro-environment, enhance the effectiveness of existing tumor immunotherapy.
, the project has launched Clinical Phase 1 studies in several hospitals in the United States and China.
October, the product was approved by the FDA as an orphan drug for the treatment of esophageal cancer and could be used to support the drug's global development of esophageal cancer adaptation.
it's worth noting that in June, Garcos Pharmaceuticals and AbbVie announced a global strategic partnership to jointly develop and commercialize SHP2 inhibitors that act on key targets for cancer cells and immune cells.
the agreement, AbbVie will be granted exclusive license to Garcos Pharmaceuticals' SHP2 program.
addition to the two products mentioned above, Garcos Pharmaceuticals' research projects include clinical bromine domain and ultra-end domain end (BET) inhibitor JAB-8263; 1000, is expected to file AND applications in the U.S. and China in the first half of 2021, as well as several drug candidates at an early stage that target several major and critical cancer signaling pathfours involving cancer, including RB, tumor immunity, and tumor metabolic signaling path.
congratulations to Garcos Pharmaceuticals on its hearing through the HKEx and hopes to bring innovative therapies to patients at an early date with the help of capital.
。